Mass balance and metabolite profiling of 14 C-guadecitabine in patients with advanced cancer

Summary Purpose The objective of this mass balance trial was to determine the excretory pathways and metabolic profile of the novel anticancer agent guadecitabine in humans after administration of a 14C-radiolabeled dose of guadecitabine. Experimental design Included patients received at least one cycle of 45 mg/m2 guadecitabine subcutaneously as once-daily doses on Days 1 to 5 of a 28-day cycle, of which the 5th (last) dose in the first cycle was spiked with 14C-radiolabeled guadecitabine....

Latest Results for Investigational New Drugs

Fri Oct 11, 2019 03:00

Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: Evidence from the Department of Veterans Affairs

Publication date: Available online 11 October 2019Source: BrachytherapyAuthor(s): Alexander N. Slade, Bassam Dahman, Michael G. ChangAbstractPurposeAfrican American men have historically had poorer prostate cancer biochemical and survival outcomes than Caucasians. However, emerging data suggest nononcologic factors drive much of this disparity. Prior evidence has suggested an association between a transient prostate specific antigen (PSA) bounce and improved biochemical control. However, racial differences...

Brachytherapy

Fri Oct 11, 2019 18:56

Vaginal cuff brachytherapy in the adjuvant setting for patients with high-risk early-stage cervical cancer

Publication date: Available online 10 October 2019Source: BrachytherapyAuthor(s): Geovanne Pedro Mauro, Rodolpho Truffa Kleine, Samantha Cabral Severino da Costa, Heloísa A. CarvalhoAbstractPurposeTo evaluate local control and survival of high-risk patients with early-stage cervical cancer submitted or not to vaginal cuff brachytherapy in the postoperative setting.Methods and MaterialsIn this retrospective cohort of patients treated from 2010 to 2017, patients were eligible if they had confirmed...

Brachytherapy

Fri Oct 11, 2019 18:56

Potential skin protective effects after UVB irradiation afforded by an antioxidant peptide from <em>Odorrana andersonii</em>

Publication date: December 2019Source: Biomedicine & Pharmacotherapy, Volume 120Author(s): Saige Yin, Ying Wang, Naixin Liu, Meifeng Yang, Yan Hu, Xiaojie Li, Yang Fu, Mingying Luo, Jun Sun, Xinwang YangAbstractWith increasing demand, the development of new natural antioxidants has become a primary direction of scientific research. We previously identified a short gene-encoded peptide (OA-VI12) from Odorrana andersonii frog skin secretions that exerted direct scavenging capacity against free...

Biomedicine & Pharmacotherapy

Fri Oct 11, 2019 18:17

Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel

Publication date: December 2019Source: Biomedicine & Pharmacotherapy, Volume 120Author(s): Xiao Xu, Jingkui Xu, Chongyu Zhao, Xiuying Hou, Mengjia Li, Liwei Wang, Lixin Chen, Yehui Chen, Linyan Zhu, Haifeng YangAbstractThe enhancement of the anticancer activity by disulfiram (DSF) chelated with copper (DSF/Cu2+) has been investigated recently, while the underlying molecular mechanisms still need to be fully elucidated. Chloride channel-3 (ClC-3) is over-expressed in a variety of cancers and involves...

Biomedicine & Pharmacotherapy

Fri Oct 11, 2019 18:17

<em>Platycodon grandiflorus</em> enhances the effect of DDP against lung cancer by down regulating PI3K/Akt signaling pathway

Publication date: December 2019Source: Biomedicine & Pharmacotherapy, Volume 120Author(s): Yang Li, Yayun Wu, Qi Xia, Ya Zhao, Ruizhi Zhao, Shigui DengAbstractCisplatin (DDP) is a first-line drug for non-small cell lung cancer (NSCLC), but its efficacy and applications are constrained by intolerance and serious side effects. Platycodon grandiflorus (PG) is usually used as lung medicinal drug to enhance other drug’s effect on lung diseases. Therefore, present study aim to investigate anti-NSCLC...

Biomedicine & Pharmacotherapy

Fri Oct 11, 2019 18:17

Management of Spastic Paresis and Cervical Dystonia: access to Therapeutic Innovations Through an International Program of Practical Courses

Publication date: Available online 10 October 2019Source: Clinical TherapeuticsAuthor(s): Carlo Colosimo, Roongroj Bhidayasiri, Klemens Fheodoroff, Kailash Bhatia, Tae Mo Chung, Therese Landreau, Luis Jorge JacintoAbstractPurposeOur purpose was to determine satisfaction and confidence of the Ixcellence Network training program on health care practitioners using botulinum toxin A (BoNT-A) for neurologic disorders, including spastic paresis and cervical dystonia.MethodsThe Ixcellence Network training...

Clinical Therapeutics

Fri Oct 11, 2019 18:10

Cost-Effectiveness of Osimertinib as a Second-Line Treatment in Patients With <em>EGFR</em>-mutated Advanced Non–Small Cell Lung Cancer in China

Publication date: Available online 10 October 2019Source: Clinical TherapeuticsAuthor(s): Haijing Guan, Gordon Liu, Feng Xie, Yanan Sheng, Luwen ShiAbstractPurposeTo assess the cost-effectiveness of osimertinib used as a second-line treatment after failure of epidermal growth factor receptor tyrosine kinase inhibitor therapy for advanced non–small cell lung cancer (NSCLC) in China.MethodsFrom the perspective of China's health care system, a Markov model was used for estimating the costs and health...

Clinical Therapeutics

Fri Oct 11, 2019 18:10

Predictors of High-cost Patients With Noninfectious Inflammatory Eye Diseases

Publication date: Available online 10 October 2019Source: Clinical TherapeuticsAuthor(s): Winnie W. Nelson, J. Bradford Rice, Alan G. White, Michaela Johnson, Julie Reiff, Antonio Flavio Lima, Laura Bartels-Peculis, Gosia Ciepielewska, Thomas A. AlbiniAbstractPurposeNoninfectious inflammatory eye diseases (NIIEDs), such as uveitis, is a general term used to describe a complex mix of acute, chronic, allergic, and inflammatory disorders. Prior literature has established that, in addition to severe...

Clinical Therapeutics

Fri Oct 11, 2019 18:10